The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
HOME > REGULATORY
REGULATORY
- Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics
December 27, 2011
- PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
- Reevaluation Recommended for Lysozyme, Pronase
December 26, 2011
- Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure
December 26, 2011
- Development Request Withdrawn for Mitoxantrone
December 26, 2011
- Application Based on Data from Public Domain Recommended for 6 APIs Including Amlodipine
December 26, 2011
- ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW
December 26, 2011
- MIPO to Begin Preparing for Drug Discovery Support Organization
December 26, 2011
- 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation
December 22, 2011
- PAC Recommends Approval for Products Recommended by PAFSC’s Committee on Drugs
December 22, 2011
- CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year
December 22, 2011
- Sanofi-aventis Selected for METI Subsidy to Build Regional HQ in Japan
December 22, 2011
- Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”
December 21, 2011
- Pharmaceutical Affairs Strategy Consultation: 98 Registrations for Preliminary Meetings, Increasing Numbers from Universities
December 21, 2011
- PMDA to Provide Prior Assessment Consultation Service for 10 APIs in FY2011
December 21, 2011
- Gov’t Approves 4th Supplementary Budget at Cabinet Meeting, Prolongs Public Subsidy for Vaccine Programs
December 21, 2011
- Bill Payers Seek Revision of Ryotan-kisoku to Increase Generic-name Prescriptions
December 21, 2011
- Chuikyo Approves Plan to Revise DPC System
December 21, 2011
- 73% of Applications for ADR Relief Processed within 8 Months in April-October: PMDA
December 21, 2011
- MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts
December 19, 2011
ページ
As Japan moves into elaborate discussions on the potential reform of its cost-effectiveness assessment (CEA) in FY2024, members of a…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
The Japanese government on September 12 approved Moderna’s updated monovalent COVID-19 vaccine directed at the Omicron XBB.1.5 strain, following its…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…